Clinical Trial Update: The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is investigating whether the time-of-day dosing of EV/P (enfortumab vedotin plus pembrolizumab) influences objective response rate in adults wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Guliz Ozgun | Conditions: Advanced Bladder Cancer | Phase 3 | Status: NOT_YET_RECRUITING